Medincell's Pivot: Sacrificing Profit for a Royalty-Driven Future

MONTPELLIER, France – June 16, 2026

Medincell, the French biopharmaceutical firm behind a novel long-acting injectable (LAI) technology, has reported financial results that paint a clear picture of strategic transformation. While the headline figures show a €20.8 million operating loss for fiscal year 2025-26, a deeper dive reveals a calculated pivot away from unpredictable milestone payments towards a more stable, high-margin future built on recurring royalties, a strategy validated by the booming success of its first commercial product, UZEDY®.

The company's total revenues of €24.3 million were impacted by the absence of large, non-recurring milestone payments seen in the previous year. However, the report’s most telling figure is the €9.3 million in royalties from UZEDY®, a treatment for schizophrenia and bipolar I disorder. This royalty stream now accounts for 38% of total revenue, up from just 22% the year prior, signaling a fundamental and intentional shift in the company's business model. This is the core of the company's 'Shift to Growth' strategy, as it trades short-term profit for a more sustainable and predictable revenue engine.

Fueling the Growth Engine

Medincell's operating loss is not a sign of distress but rather a direct consequence of deliberate investment. The company increased operating expenses by 17% to €45.0 million, with the lion's share dedicated to expanding its research and development pipeline. R&D expenses alone accounted for €26.5 million, a clear commitment to leveraging its proprietary BEPO® technology platform across new therapeutic areas.

This aggressive investment strategy is backstopped by a significantly strengthened balance sheet. In March 2026, the company successfully raised €48.2 million from top-tier US and European healthcare investors, boosting its total liquidity to a robust €84.8 million. This capital infusion is earmarked not just for internal R&D but also to enhance its negotiating position in future partnerships, allowing it to demand more favorable terms and greater participation in downstream royalties.

Christophe Douat, CEO of Medincell, framed the year as a pivotal transition. “FY 2025–26 reflects an important transition phase for Medincell,” he stated in the release. “Building on UZEDY’s strong performance and the expected commercial launch of Olanzapine LAI by our partner Teva later this year, we are advancing the next phase of our ‘Shift to Growth’ strategy.”

This strategy involves building a pipeline designed to deliver sustainable value by generating not just milestones, but more importantly, “recurring high-margin revenues over time.” For investors, this signals a move toward a more conventional and scalable biopharma model, where the initial risk of R&D gives way to long-term cash flow from commercialized products.

UZEDY®: The Blueprint for Success

The confidence to undertake this strategic pivot stems directly from the market validation provided by UZEDY®. Commercialized by partner Teva Pharmaceuticals, UZEDY® has become the fastest-growing LAI in its category. Teva reported net sales for the product reached an impressive $215 million in fiscal year 2026, a 52.5% increase year-over-year, and has guided for sales between $250 million and $280 million for the current year.

More than just a financial success, UZEDY® serves as a powerful proof-of-concept for the entire Medincell platform. The core value proposition of LAI technology is improving patient adherence, a critical challenge in chronic illnesses like schizophrenia. Real-world data demonstrates UZEDY®'s impact, showing patients experienced significantly lower relapse rates (9.0% vs. 15.4% for oral alternatives) and better treatment adherence (71.3% vs. 52.8%). This improved adherence translates directly into better patient outcomes and lower overall healthcare costs, a compelling argument for payers and providers.

The success validates Medincell's technology in a global LAI market projected to grow from around $21.5 billion in 2026 to over $65 billion by 2034. With psychiatric disorders commanding the largest share of this market, Medincell is perfectly positioned to capitalize on this trend.

A Pipeline Primed for Value

With UZEDY® providing a steady royalty base, all eyes now turn to the next major catalyst in Medincell’s pipeline: Olanzapine LAI (mdc-TJK), another schizophrenia treatment being developed with Teva. The New Drug Application was accepted by the FDA in February 2026, with a regulatory decision expected in the fourth quarter. Teva is preparing for a potential U.S. launch before year-end.

Critically, Phase 3 data showed the treatment was effective without any reported cases of Post-Injection Delirium/Sedation Syndrome (PDSS), a serious side effect that has limited the use of other long-acting olanzapine formulations. This key safety differentiator could unlock a significant market opportunity. Upon approval, Medincell stands to receive milestone payments and a second stream of mid- to high-single-digit royalties.

Beyond this near-term catalyst, the pipeline shows strategic depth. A collaboration with biopharma giant AbbVie on a central nervous system candidate is advancing, with clinical development expected to begin in 2027. This partnership alone holds the potential for up to $315 million in milestones per program plus royalties. Furthermore, with 15 active programs in formulation, including a Phase III-ready candidate for post-surgical pain, Medincell is building a diversified portfolio that reduces reliance on any single product or partner. This methodical expansion is precisely what the recent fundraising and increased R&D spend are designed to achieve, setting the stage for the company's evolution into a multi-product, royalty-generating biopharmaceutical player.